FSTL1 and Hepatic fibrosis: Consistent with the results of MSC-based therapy, we also found that MNCs significantly ameliorated liver fibrosis in wild-type mice but showed no functional benefit on liver fibrosis in Fstl1+/− mice (Supplementary Fig. 4b–e).